Related Experiment Video
Updated: Aug 21, 2026

Restraint to Induce Stress in Mice and Rats
Published on: December 6, 2024
Noradrenergic alpha-2 agonists have anxiolytic-like actions on stress-related behavior and mesoprefrontal dopamine
Bret A Morrow1, Tony P George, Robert H Roth
1Laboratory of Neuropsychopharmacology, Department of Psychiatry, Yale University School of Medicine, 333 Cedar St., New Haven, CT 06520-8066, USA.
Abstract:
Clonidine (CLON), an alpha-2 agonist, has anxiolytic-like actions on the response of mesoprefrontal dopamine (DA) neurons to aversive stimuli in addition to some fear-related behavioral responses. We hypothesized that the anxiolytic-like actions of clonidine could be mimicked by stimulation of alpha-2 receptors on the mesoprefrontal dopamine neurons. Here, we test this hypothesis using clonidine or guanfacine (GFC), another alpha-2 agonist, in a model of aversive conditioning that selectively activates the mesoprefrontal dopamine neurons. One day prior to testing with drugs, rats were conditioned to fear a soft tone by pairing it with a footshock. During testing, the animals were subjected to the tones alone after drugs were administered systemically, or by local infusion into the regions containing the cell bodies and terminals of the mesoprefrontal dopamine neurons, namely, the ventral tegmental area (VTA) and the prelimbic (PL) cortex. Systemic administration of guanfacine blocked the increase in immobility in response to the conditioned tone and prevented the stress-associated increase in dopamine turnover in the prelimbic cortex. Systemic clonidine also prevented the stress-associated increase in dopamine turnover but caused sedation preventing behavioral measures. Guanfacine was then used in all local injection studies. The local application of guanfacine into either the prelimbic cortex or the ventral tegmental area did not prevent the conditioned fear-induced increase in dopamine turnover or the increase in immobility in response to the conditioned tones. We conclude that the anxiolytic-like actions of alpha-2 agonists are not due to binding to alpha-2 receptors on the stress-sensitive mesoprefrontal dopamine neurons.
Related Concept Videos
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drugs Affecting Neurotransmitter Release or Uptake
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Adrenergic Agonists: Therapeutic Classification
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...

